Kallisio Secures CE Mark for Stentra™ Precision Oral Immobilization System
Kallisio has announced a significant regulatory milestone with the CE certification of its innovative Stentra intraoral positioning system under the European Union’s Medical Device Regulation, EU MDR 2017/745. This certification clears the way for the commercialization of Stentra across the European Economic Area (EEA), marking an important step forward in expanding access to advanced, patient-specific solutions in radiation oncology. The company has indicated that the initial rollout of the system will begin in Germany, where selected clinical pilot sites will evaluate its real-world implementation and benefits.
Stentra is a highly specialized intraoral device designed for use by trained healthcare professionals during the planning and delivery of radiation therapy for patients with head and neck cancers. In radiation oncology, precise and consistent patient positioning is critical to ensure that high doses of radiation are accurately delivered to tumors while minimizing exposure to surrounding healthy tissues. Even slight variations in positioning can significantly affect treatment outcomes, making reliable immobilization systems essential.
What distinguishes Stentra from traditional positioning solutions is its patient-specific design. Each device is tailored to the unique anatomy and clinical needs of the individual patient, enabling highly accurate and reproducible positioning throughout the course of treatment. The system is engineered to provide stability and consistency across multiple radiation therapy sessions, helping clinicians maintain precise targeting of tumors while reducing variability.
A key advantage of the Stentra system lies in its seamless integration into existing clinical workflows. Unlike some advanced technologies that require significant changes to hospital infrastructure, Kallisio Stentra is designed to work within the current ecosystem of radiation therapy planning and delivery. It does not require modifications to treatment planning systems, IT infrastructure, or data integration processes. This ease of adoption is expected to facilitate rapid uptake among clinics, as it minimizes operational disruption while delivering enhanced precision.
Kallisio’s broader platform combines advanced design automation, rapid 3D manufacturing, and digital workflow integration to create customized treatment solutions at scale. The Stentra system exemplifies this approach by leveraging digital tools to transform patient-specific data into a physical device optimized for clinical use. The workflow begins with scan acquisition, typically using imaging modalities already available in clinical settings. This data is then processed through automated design systems to generate a device that precisely matches the patient’s anatomy and treatment requirements. The final product is manufactured using advanced 3D printing technologies and delivered for use in the clinic.
This digital-first approach not only improves efficiency but also ensures a high degree of accuracy and reproducibility. By aligning the design and manufacturing processes with clinical intent, Stentra enables millimeter-level precision in patient positioning. Such accuracy is particularly important in head and neck cancers, where tumors are often located near critical structures such as the salivary glands, spinal cord, and oral mucosa.
One of the notable clinical benefits of Stentra is its ability to displace organs at risk (OARs) away from the radiation field. By physically repositioning structures such as the tongue or other soft tissues, the device helps reduce unintended radiation exposure to healthy areas. This Kallisio capability can lead to a reduction in radiation-induced side effects, including conditions like oral mucositis, which is a common and often debilitating complication of head and neck radiation therapy.
In addition to improving safety, Stentra is designed to enhance patient comfort and treatment tolerance. Traditional immobilization methods can sometimes be uncomfortable, particularly when used repeatedly over several weeks of treatment. By creating a device that is customized to the patient’s anatomy, Kallisio aims to provide a more comfortable experience, which may improve patient compliance and overall treatment success.
The system offers multiple configurations to support different clinical strategies. Physicians can choose from options that enable tongue depression, elevation, or lateralization, depending on the specific requirements of the treatment plan. This flexibility allows clinicians to tailor positioning techniques to each patient’s tumor location and therapeutic goals, further enhancing the precision of radiation delivery.
Clinical experts have expressed optimism about the potential impact of the technology. Stefan Rieken, Director of the Department of Radiation Therapy and Radiation Oncology at Universitätsmedizin Göttingen in Germany, highlighted the significance of improved positioning accuracy in head and neck cancer treatment. He noted that Stentra represents a meaningful advancement in achieving consistent patient positioning during radiation therapy and emphasized his interest in its potential to reduce the incidence of oral mucositis, a condition that can significantly affect patients’ quality of life.
From a strategic perspective, the CE certification represents a critical step in Kallisio’s mission to expand access to precision oncology solutions. Rajan Patel, Chief Executive Officer of Kallisio, underscored the importance of this milestone in bringing patient-specific technologies to a broader audience. He emphasized the company’s commitment to equipping clinicians with tools that integrate seamlessly into existing workflows while enhancing precision and consistency in treatment delivery.
The initial deployment of Stentra in Germany will serve as a foundation for broader adoption across Europe. By collaborating with selected clinical pilot sites, Kallisio aims to generate real-world evidence demonstrating the system’s effectiveness and value in routine practice. These pilot programs are expected to play a crucial role in refining the technology, gathering user feedback, and supporting wider commercialization efforts.
To further support adoption, Kallisio has introduced a limited Proof-of-Value pilot program for clinics interested in integrating Stentra into their practice. This initiative provides healthcare providers with an opportunity to evaluate the system’s clinical and operational benefits before committing to broader implementation. Such programs are particularly valuable in the healthcare sector, where new technologies must demonstrate both clinical efficacy and economic viability.
The introduction of Stentra comes at a time when the field of radiation oncology is increasingly focused on precision medicine. Advances in imaging, treatment planning, and delivery technologies have significantly improved the ability to target tumors with high accuracy. However, patient positioning remains a critical factor that can influence treatment outcomes. By addressing this challenge with a patient-specific, technology-driven solution, Kallisio is contributing to the ongoing evolution of cancer care.
Looking ahead, the company’s integrated approach—combining digital design, advanced manufacturing, and clinical integration—positions it well to expand its portfolio of precision oncology solutions. As healthcare systems continue to prioritize personalized medicine and improved patient outcomes, technologies like Stentra are likely to play an increasingly important role.
In summary, the CE certification of the Stentra intraoral positioning system marks a major milestone for Kallisio and for the field of radiation oncology. By enabling highly accurate, patient-specific positioning without disrupting existing workflows, the system has the potential to improve treatment precision, reduce side effects, and enhance the overall patient experience. With its initial launch in Germany and plans for broader European expansion, Stentra represents a promising advancement in the quest for more precise and effective cancer therapies.
Source Link:https://www.businesswire.com/
